research UTMD Enhances Targeting of Diclofenac and Doxil® to Boost Tumor Immunotherapy
UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.
Search
for
Sort by
Research
600-630 / 1000+ results
research Liposomes in cancer therapy
Liposomes show promise in cancer treatment by delivering drugs with less toxicity and improved effectiveness.
research Three cases of androgen‐dependent disease associated with myotonic dystrophy
Women with myotonic dystrophy might get diseases related to male hormones because their body tissues are extra sensitive to these hormones.
research The significance of the apelinergic system in doxorubicin-induced cardiotoxicity
The apelinergic system might protect the heart from damage caused by doxorubicin.
research A novel derivative of doxorubicin, AD198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitro
AD198 is more effective than doxorubicin in stopping certain dog cancer cells.
research Minoxidil (Mx) as a prophylaxis of doxorubicin – induced alopecia
Minoxidil not effective in preventing chemotherapy-induced hair loss.
research Effects of Mitoquinone on Doxorubicin-Induced Cytotoxicity in H9c2 Cardiac Myoblasts and 22Rv1 Prostate Cancer Cells
Mitoquinone protects heart cells from doxorubicin damage and slightly boosts its effect on prostate cancer cells.
research Safety and efficacy of low-dose metronomic cyclophosphamide plus vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
The treatment is safe and shows promise for metastatic breast cancer.
research Effect of norplant on androgens and sexual function
Norplant implants lower some androgen levels but don't significantly change sexual function.
research Mitoxantrone, Etoposide and Prednisolone—a Novel Combination in The Treatment of Relapsed and Refractory Lymphoma
The combination of mitoxantrone, etoposide, and prednisolone is effective for treating relapsed lymphoma with manageable side effects.
research High-dose alpha-tocopherol as a preventive of doxorubicin-induced alopecia.
Alpha-tocopherol does not prevent hair loss from doxorubicin.
research Weekly docetaxel in minimally pretreated cancer patients: A dose-escalation study focused on feasibility and cumulative toxicity of long-term administration
Giving docetaxel weekly at 40 mg/m² is manageable and has low toxicity for cancer patients.
research Doxetaxel: new indication. Prostate cancer: a few more weeks.
Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.
research Docetaxel.
Docetaxel is effective against various cancers but mainly causes neutropenia.
research Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
research Gemcitabine in combination with vinorelbine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer
The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.
research ENDOXAN ALOPECIA
Endoxan often causes hair loss, which usually starts in the third week of treatment.
research Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I–II feasibility study
The treatment combining docetaxel, cisplatin, and 5-FU is feasible and effective for advanced head and neck cancer.
research Cystitis Due to Cytoxan: Case Report
A woman developed severe bladder inflammation after cancer treatment with Cytoxan.
research [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine].
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
research Transarterial chemoembolization (TACE) combined with donafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A real-world clinical study.
The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.
research High incidence of severe hand–foot syndrome during capecitabine–docetaxel combination chemotherapy
About half the patients treated with capecitabine and docetaxel developed severe hand-foot syndrome.
research Prevention of doxorubicin-induced alopedia by scalp hypothermia: relation to degree of cooling.
Cooling the scalp below 22°C before and during chemotherapy can help prevent hair loss.
research Clinical observation of simultaneous continuous infusion of fluorouracil and disodium folinate combined with oxaliplatin for metastatic colorectal cancer
Disodium folinate can safely and effectively replace calcium folinate in colorectal cancer treatment.
research Results of Ifosfamide Combination Chemotherapy in Patients with Advanced Soft Tissue Sarcomas
Adriamycin and ifosfamide together work best for advanced soft tissue sarcomas.
research Prevention of chemotherapy drug-mediated human hair follicle damage: combined use of cooling with antioxidant suppresses oxidative stress and prevents matrix keratinocyte cytotoxicity
Cooling with antioxidants helps protect hair during chemotherapy.
research Hair Follicle–Derived Blood Vessels Vascularize Tumors in Skin and Are Inhibited by Doxorubicin
Doxorubicin can block blood vessels from hair follicles, reducing skin tumor growth.
research Prevention of erlotinib-induced folliculitis with doxycycline
Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.
research Used Right, IV Arsenic Is Safe & Effective
Intravenous arsenic is safe and effective for treating certain blood cancers.
research Arsenic Trioxide as Effective Therapy for Relapsed Acute Promyelocytic Leukemia
Arsenic trioxide effectively treats relapsed acute promyelocytic leukemia with manageable side effects.